Merck Announces Positive Phase II Results for Investigational ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
DARMSTADT, Germany, Sept. 10, 2020 /PRNewswire-AsiaNet/ -- Not intended for UK and US based media- Sonelokinab is an investigational IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F - Phase II study was facilitated by Avillion as part of an innovative co-development modelMerck, ...
Authors: LATEST ASIANET NEWS RELEASES